Clinical Trial: Phase I/II Study of hLL1 in Multiple Myeloma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: A Phase I/II Study of Immunotherapy With hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients With Multiple Myeloma

Brief Summary: This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments.